That said, there are good reasons to believe a one-dose schedule may not be as efficacious as a two-dose schedule, including against severe disease in high-risk populations, due to magnitude, duration and quality of the immune response. 3/
-
-
In sum, push for trial now, maybe we get one hopefully quick. Raise the topic now, maybe we can fight unsupported ossification of practice... Just getting to that point would be excellent I think, rather than inertia!
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
This Tweet is unavailable.
-
Yeah. But every side of this is peril. I'm also worried about losing the placebo arm after the EUA, and that we're not doing some regular/random swabs in the trials. Also why a unified protocol? The age risk gradation is steep for 65+ (maybe another booster? Anyone checking?)
- Show replies
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.